Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) Return on Equity (2022 - 2025)

Summit Therapeutics' Return on Equity history spans 4 years, with the latest figure at 0.29% for Q3 2025.

  • For Q3 2025, Return on Equity rose 36.0% year-over-year to 0.29%; the TTM value through Sep 2025 reached 0.29%, up 36.0%, while the annual FY2024 figure was 1.01%, 501.0% up from the prior year.
  • Return on Equity reached 0.29% in Q3 2025 per SMMT's latest filing, up from 0.42% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.18% in Q3 2022 to a low of 6.89% in Q4 2023.
  • Average Return on Equity over 4 years is 2.12%, with a median of 0.65% recorded in 2024.
  • Peak YoY movement for Return on Equity: crashed -660bps in 2023, then skyrocketed 632bps in 2024.
  • A 4-year view of Return on Equity shows it stood at 0.29% in 2022, then plummeted by -2303bps to 6.89% in 2023, then soared by 92bps to 0.57% in 2024, then skyrocketed by 49bps to 0.29% in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Return on Equity are 0.29% (Q3 2025), 0.42% (Q2 2025), and 0.52% (Q1 2025).